Biogen Expands Antisense Drug Pipeline With Alloy Platform Deal

Biogen partners with Alloy Therapeutics to advance RNA-targeting therapies, building on its growing immunology and rare disease portfolio.

Apr. 7, 2026 at 12:54pm

Got story updates? Submit your updates here. ›

A minimalist studio still life featuring a collection of polished, geometric objects made from premium materials like glass, metal, and stone, arranged elegantly on a clean, monochromatic background to symbolize the abstract concepts of drug discovery, RNA-targeting technology, and pharmaceutical innovation.Biogen's partnership with Alloy Therapeutics aims to leverage advanced platform technologies to enhance the efficiency and potential of RNA-based drug development.Waltham Today

Biogen, the Massachusetts-based biopharmaceutical company, has announced a partnership with Alloy Therapeutics to advance its antisense drug pipeline using Alloy's AntiClastic ASO platform. The deal will provide Biogen with access to Alloy's technology designed to improve the effectiveness of RNA-targeting therapeutics, addressing longstanding challenges in the field around drug potency and biodistribution. In return, Alloy will receive an upfront payment as well as potential milestone-based compensation and royalties on any commercialized products.

Why it matters

This collaboration reflects Biogen's strategic focus on expanding its pipeline in immunology and rare diseases through innovative platform technologies. Alloy's diversified model integrates computational and AI-driven tools to enhance drug discovery and optimization, which aligns with Biogen's goal of leveraging advanced platforms to improve the efficiency and potential of RNA-based therapeutics.

The details

Under the terms of the agreement, Alloy Therapeutics will receive an upfront payment from Biogen and stands to earn additional milestone-based compensation, along with tiered royalties on any commercialized products arising from the partnership. Alloy's AntiClastic ASO platform is designed to improve the effectiveness of antisense therapeutics by enabling drug developers to target disease pathways at the RNA level within cells, addressing longstanding challenges in the field around drug potency and therapeutic index.

  • The partnership between Biogen and Alloy Therapeutics was announced on April 7, 2026.

The players

Biogen

A Massachusetts-based biopharmaceutical company focused on developing therapies for immunology and rare diseases.

Alloy Therapeutics

A diversified platform company based in Waltham, Massachusetts, that integrates computational and AI-driven tools to accelerate drug discovery and optimization.

Got photos? Submit your photos here. ›

The takeaway

By partnering with Alloy Therapeutics, Biogen is positioning itself to leverage advanced platform technologies to improve the efficiency and potential of its RNA-based therapeutic pipeline, further strengthening its capabilities in immunology and rare diseases.